Isaac, Krista M.
Portell, Craig A.
Williams, Michael E.
Article History
Accepted: 20 May 2021
First Online: 16 July 2021
Declarations
:
: Krista M. Isaac declares that she has no conflict of interest. Craig A. Portell has received research funding from AbbVie, BeiGene, Kite/Gilead, Genentech, TG Therapeutics, Acerta, Infinity Pharmaceuticals/Verastem Oncology, and VelosBio and has received compensation from Amgen, BeiGene, Janssen, Pharmacyclics, Kite Pharma/Gilead Sciences, MorphoSys, and Genentech for service as a consultant. Michael E. Williams has received clinical trial support (paid to the University of Virginia) from Janssen, Pharmacyclics, TG Therapeutics, Gilead Sciences, and Celgene; has contributed to a lymphoma registry sponsored by Allos Therapeutics; has received speaker’s honoraria from Xian Janssen Pharmaceutical Ltd.; and has received compensation from Celgene, Gilead Sciences, TG Therapeutics, AbbVie, Kite Pharma, Juno Pharmaceuticals, Verastem Oncology, Seattle Genetics, Sandoz, AstraZeneca, and Kymera Therapeutics for participation on advisory boards.